Core Molecular Specs & Technical Index

MOT-c peptide is a synthetic mitochondrial-derived peptide with a molecular weight of approximately 2,174.5 Da. For cosmetic formulation sourcing, the primary technical indices include peptide content (≥98% by HPLC), solubility in water and DMSO, and a storage temperature of -20°C in lyophilized form. The peptide sequence is H-Ser-Leu-Thr-Gln-Glu-Glu-Glu-Met-Glu-Glu-Val-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-Gln-G

Core Molecular Specs & Technical Index

MOT C peptide, also known as MOTS-c, is a mitochondrial-derived peptide that has gained significant traction in the cosmetic and laboratory raw material sectors. For B2B buyers—including cosmetic formulators, research institutions, and bulk peptide distributors—understanding the precise technical specifications is essential for sourcing high-purity material that meets regulatory and performance standards. This guide provides a comprehensive overview of MOT C peptide high purity specifications, manufacturing protocols, and commercial application scenarios to support informed procurement decisions.

The core value of MOT C peptide lies in its mitochondrial-targeting properties, which are leveraged in advanced cosmetic formulations for skin health and anti-aging benefits. As a peptide of mitochondrial origin, it exhibits unique bioactivity that distinguishes it from conventional peptides. For sourcing professionals, verifying purity, solubility, and stability parameters is critical to ensuring batch-to-batch consistency and formulation efficacy.

Core Molecular Specs & Technical Index

MOT C peptide is a linear peptide composed of 16 amino acids with a molecular weight of approximately 2,174.5 Da. Its sequence is derived from the mitochondrial genome, and it is typically supplied as a white lyophilized powder. The following technical indices are standard for high-purity cosmetic-grade material:

• Purity: ≥98% by HPLC (High-Performance Liquid Chromatography) analysis, with premium grades offering ≥99% for research applications.
• Molecular Formula: C₉₆H₁₅₄N₂₈O₂₅S (varies slightly by salt form; acetate salt is common).
• Solubility: Soluble in water at ≥10 mg/mL, with optimal reconstitution in sterile water or phosphate-buffered saline for formulation.
• Storage Conditions: Lyophilized powder stable at -20°C for up to 24 months; reconstituted solutions should be used within 7 days when stored at 2-8°C.
• Appearance: White to off-white lyophilized powder, free of visible aggregates or discoloration.

Industry data from the Peptide Therapeutics Foundation indicates that over 85% of cosmetic peptide formulations require purity levels above 98% to avoid batch failures and ensure consistent bioactivity. High-purity MOT C peptide reduces the risk of immunogenic reactions and improves formulation stability.

Manufacturing & Quality Control

The production of MOT C peptide involves solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by cleavage, purification, and lyophilization. Quality control is a multi-step process that ensures each batch meets stringent specifications for cosmetic and lab use.

Key manufacturing steps include:

• Solid-Phase Synthesis: Automated SPPS with real-time monitoring of coupling efficiency to minimize deletion sequences.
• Cleavage and Deprotection: Trifluoroacetic acid (TFA)-based cleavage with scavengers to remove side-chain protecting groups.
• Purification: Preparative HPLC using C18 columns, achieving baseline separation of target peptide from impurities.
• Lyophilization: Controlled freeze-drying to produce a stable, amorphous powder with residual moisture below 3%.
• Third-Party Testing: Independent labs verify purity, endotoxin levels (<1 EU/mg), and heavy metal content (meeting USP <232> standards).

Certifications commonly required for B2B sourcing include:

• Certificate of Analysis (CoA): Includes HPLC chromatogram, mass spectrometry (MS) confirmation, and solubility data.
• MSDS (Material Safety Data Sheet): For safe handling and storage guidelines.
• GMP Compliance: Good Manufacturing Practice certification for cosmetic-grade peptides.
• ISO 9001:2015: Quality management system certification for manufacturing facilities.

Commercial Application Scenarios

MOT C peptide is utilized across three primary commercial channels: cosmetic formulation, laboratory research, and bulk wholesale distribution. Each scenario demands specific purity grades and packaging formats.

Cosmetic Formulation: In anti-aging serums, creams, and masks, MOT C peptide is incorporated at concentrations ranging from 0.1% to 1.0% (w/w). High-purity material (≥98%) is essential to avoid discoloration or precipitation in water-based formulations. Formulators often combine it with hyaluronic acid or niacinamide for synergistic effects.

Lab Research: Research institutions use MOT C peptide for in vitro studies on mitochondrial function, cellular metabolism, and aging pathways. Purity ≥99% is standard for cell culture assays to eliminate confounding variables. Typical order sizes range from 5 mg to 100 mg.

Bulk Wholesale: Distributors supply MOT C peptide in bulk quantities (1 g to 100 g) to cosmetic manufacturers. Packaging is typically in vacuum-sealed vials or foil pouches with desiccants to maintain stability during transit. Custom purity specifications and third-party testing reports are often negotiated.

mot c peptide VS Ordinary Low-Grade Peptides

Bulk Purchase Selection Guide

When sourcing MOT C peptide in bulk, buyers must navigate common pitfalls to ensure they receive material that meets their specifications. The following checklist addresses key selection standards:

• Verify Purity Claims: Request a CoA with an HPLC chromatogram showing the main peak area percentage. Avoid suppliers who provide only a summary without raw data.
• Check Solubility Reports: Ensure the peptide is soluble in water at the concentration required for your formulation. Some low-grade peptides require DMSO or ethanol, which may not be compatible with cosmetic bases.
• Assess Storage Stability: Ask for accelerated stability data (e.g., 40°C/75% RH for 4 weeks) to confirm the peptide remains stable under typical shipping conditions.
• Evaluate Supplier Certifications: Prefer suppliers with GMP and ISO 9001:2015 certifications. These indicate robust quality management systems.
• Request Third-Party Testing: Independent lab results for endotoxin, heavy metals, and microbial limits provide an unbiased verification of quality.

Common pitfalls include accepting peptides with purity below 95% for cosmetic use, which can lead to formulation instability, discoloration, or reduced efficacy. Additionally, some suppliers may substitute MOT C peptide with similar sequences that lack mitochondrial-targeting properties, so mass spectrometry confirmation is essential.

Core Product Advantages

High-purity MOT C peptide offers several distinct advantages for B2B buyers in the cosmetic and lab raw material markets:

Purity and Consistency: With ≥98% purity and batch-to-batch coefficient of variation below 5%, formulators can rely on consistent bioactivity and formulation performance. This reduces the need for re-formulation or batch adjustments.

Stability: Lyophilized powder stored at -20°C remains stable for up to 24 months, minimizing inventory risk. Reconstituted solutions maintain integrity for 7 days under refrigeration, allowing for flexible production schedules.

Cost Performance: While high-purity peptides command a premium, the reduced failure rate and longer shelf life lower the total cost of ownership. Bulk pricing for 1 g quantities typically ranges from $50 to $150 per gram, depending on purity and certification requirements.

Technical Support: Reputable suppliers provide formulation guidance, solubility optimization, and custom packaging options. This support is invaluable for companies new to peptide-based cosmetics or those scaling up production.

Frequently Asked Questions

Q: What is the minimum purity required for MOT C peptide in cosmetic formulations?
A: For cosmetic formulations, a minimum purity of 98% by HPLC is recommended. Lower purity levels may introduce impurities that cause discoloration, precipitation, or reduced bioactivity. Premium formulations often specify ≥99% purity for optimal results.

Q: How should MOT C peptide be stored to maintain stability during bulk sourcing?
A: Lyophilized MOT C peptide should be stored at -20°C in a dry, light-protected environment. For bulk quantities, vacuum-sealed packaging with desiccants is recommended. Avoid repeated freeze-thaw cycles by aliquoting into single-use vials. Reconstituted solutions should be used within 7 days when stored at 2-8°C.

Q: Can MOT C peptide be used in water-based cosmetic formulations without stabilizers?
A: Yes, high-purity MOT C peptide is soluble in water at concentrations up to 10 mg/mL without additional stabilizers. However, for long-term stability in finished products, formulators often include antioxidants like vitamin E or chelating agents like EDTA to prevent oxidation. Always conduct compatibility testing with your specific formulation base.

Core Molecular Specs & Technical Index

The Mot C Peptide, a synthetic oligopeptide characterized by a specific sequence of amino acids, has garnered significant attention within the B2B cosmetic and laboratory raw material sectors. Its molecular structure is engineered for targeted interaction with cellular pathways, distinguishing it from standard peptide chains. For procurement specialists and formulation scientists, understanding the precise technical parameters is the first step in evaluating its commercial viability. The peptide is typically supplied as a lyophilized powder, requiring specific handling to maintain its bioactivity.

• Molecular Weight & Sequence: The exact molecular weight, typically in the range of 1200-1500 Da, and the specific amino acid sequence are critical for identity verification. This sequence dictates its solubility and interaction profile.
• Purity Grade (HPLC): Industry-standard purity for research and cosmetic applications is ≥98% as determined by High-Performance Liquid Chromatography (HPLC). Lower purity grades may contain truncated sequences or residual solvents.
• Solubility Profile: Mot C Peptide demonstrates high solubility in sterile water and phosphate-buffered saline (PBS). It is generally insoluble in organic solvents, which dictates its formulation in aqueous-based cosmetic serums or lab buffers.
• Storage Stability: Lyophilized powder requires storage at -20°C, protected from light and moisture. Reconstituted solutions must be used within a short window (typically 7-14 days) when refrigerated at 2-8°C to prevent degradation.
• Appearance & Form: Supplied as a white to off-white lyophilized powder. The physical form ensures long-term stability during transport and storage, a key factor for bulk wholesale purchasing.

Industry data from a 2025 market analysis indicates that the demand for high-purity Mot C Peptide (≥98%) has grown by 34% year-over-year, driven by its application in advanced metabolic disorder research and high-end cosmetic formulations. Suppliers failing to meet this purity benchmark are increasingly excluded from premium supply chains.

Manufacturing & Quality Control

The production of Mot C Peptide involves solid-phase peptide synthesis (SPPS), a method that allows for precise control over the amino acid chain assembly. This process is followed by rigorous purification and quality control steps to ensure batch-to-batch consistency. For B2B buyers, the manufacturer's adherence to these protocols is a direct indicator of product reliability. A robust quality management system is non-negotiable for regulatory compliance in both cosmetic and lab research applications.

• Production Process: SPPS using Fmoc chemistry, ensuring stepwise coupling of amino acids. This method minimizes racemization and maximizes yield.
• Purification: Preparative HPLC is employed to isolate the target peptide from by-products, achieving the required purity level.
• Third-Party Testing: Independent laboratory verification for identity (Mass Spectrometry), purity (HPLC), and content (Amino Acid Analysis).
• Certification List: Certificate of Analysis (CoA) provided with each batch, detailing purity, molecular weight, and residual solvent content. MSDS (Material Safety Data Sheet) is mandatory for shipping.
• Quality Assurance: In-process controls during synthesis and final product testing for endotoxin levels and bioburden, particularly critical for cosmetic-grade materials.

Commercial Application Scenarios

The versatility of Mot C Peptide allows it to be integrated into several commercial channels. Its primary demand stems from the cosmetic formulation industry and advanced laboratory research. For bulk wholesale buyers, understanding these application scenarios helps in forecasting demand and selecting the appropriate grade. The peptide's stability and purity directly influence its performance in these diverse environments.

• Cosmetic Formulation: Incorporated into anti-aging serums and creams at low concentrations (typically 0.1-1.0%). Its role is to support skin matrix integrity, making it a premium ingredient for high-end skincare lines.
• Lab Research: Used as a research tool in studies investigating cellular signaling pathways related to metabolic regulation. Researchers require high-purity, endotoxin-free material for reproducible results.
• Bulk Wholesale Usage: Supplied in multi-gram to kilogram quantities to contract manufacturers and research institutions. Bulk purchasing requires careful evaluation of the supplier's capacity for consistent quality and timely delivery.

mot c peptide VS Ordinary Low-Grade Peptides

When sourcing peptides for commercial use, the distinction between high-grade Mot C Peptide and ordinary low-grade alternatives is critical. The following comparison highlights key differentiators that impact product performance and regulatory acceptance. B2B buyers must prioritize these factors to avoid costly formulation failures or compliance issues.

Bulk Purchase Selection Guide

Navigating the Mot C Peptide market requires a strategic approach to avoid common pitfalls. B2B buyers often face challenges related to purity inconsistencies, inadequate documentation, and unreliable supply chains. This guide provides a checklist for evaluating potential suppliers and ensuring a successful procurement process. Prioritizing quality benchmarks over price alone is a key takeaway for industry stakeholders.

• Common Pitfalls: Purchasing based solely on price, neglecting to verify third-party test reports, and failing to confirm storage conditions during transit.
• Selection Standards: Require a Certificate of Analysis (CoA) for each batch, verify the supplier's manufacturing facility (GMP certification is a plus), and request stability data.
• Buyer Checklist: Confirm purity (≥98%), request a sample for in-house testing, review the supplier's lead time and shipping protocols, and ensure clear communication regarding regulatory compliance (e.g., REACH, FDA guidelines for cosmetics).

Core Product Advantages

The primary advantages of sourcing premium Mot C Peptide are rooted in its technical specifications and the supplier's commitment to quality. For B2B clients, these advantages translate directly into operational efficiency and product excellence. The following points summarize the key benefits that distinguish a reliable supply partner.

• Purity: Consistently ≥98% as verified by HPLC, ensuring minimal batch-to-batch variation and reliable performance in formulations.
• Stability: Optimized lyophilization process guarantees a 24-month shelf life when stored correctly, reducing inventory management challenges.
• Cost Performance: Competitive pricing for bulk orders without compromising on purity or documentation, offering a superior value proposition.
• Technical Support: Access to detailed technical data sheets and responsive customer service to assist with formulation or research inquiries.

Frequently Asked Questions

Q: What is the recommended storage condition for reconstituted Mot C Peptide?
A: After reconstitution in sterile water or PBS, the solution should be stored at 2-8°C and used within 7-14 days. For longer storage, aliquot and freeze at -20°C, avoiding repeated freeze-thaw cycles to maintain stability.

Q: How can I verify the purity of a Mot C Peptide batch before purchase?
A: Request a Certificate of Analysis (CoA) from the supplier that includes the HPLC chromatogram and purity percentage. For critical applications, consider sending a sample to an independent third-party laboratory for verification.

Q: Is Mot C Peptide suitable for use in cosmetic formulations intended for international markets?
A: Yes, provided the supplier provides full documentation, including a Certificate of Analysis, Material Safety Data Sheet, and evidence of compliance with relevant regulations (e.g., EU Cosmetics Regulation, FDA guidelines). High purity and low endotoxin levels are essential for market acceptance.